» Articles » PMID: 35630815

New Cu Complexes with N-Sulfonamide Ligands: Potential Antitumor, Antibacterial, and Antioxidant Agents

Overview
Journal Molecules
Publisher MDPI
Specialty Biology
Date 2022 May 28
PMID 35630815
Authors
Affiliations
Soon will be listed here.
Abstract

Nowadays, the discovery of a new non-toxic metal complex with biological activity represents a very active area of research. Two Cu complexes, [Cu(L1)(HO)] (C1) (HL1= N-(5-(4-methylphenyl)-[1,3,4]-thiadiazole-2-yl)-naphtalenesulfonamide) and [Cu(L2)(py)(HO)] (C2) (HL2= N-(5-ethyl-[1,3,4]-thiadiazole-2-yl)-naphtalenesulfonamide), with two new ligands were synthesized. The X-ray crystal structures of the complexes were determined. In both complexes, Cu is five-coordinated, forming a CuNO and CuNO chromophore, respectively. The ligands act as monodentate, coordinating the metal ion through a single N atom; for the C2 complex, the molecules from the reaction medium (pyridine and water) are also involved in the coordination of Cu. The complexes have a distorted square pyramidal square-planar geometry. The compounds were characterized by FT-IR, electronic EPR spectroscopy, and magnetic methods. The nuclease activity studies confirm the complexes' capacity to cleave the DNA molecule. Using a xanthine-xanthine oxydase system, the SOD mimetic activity of the complexes was demonstrated. Cytotoxicity studies were carried out on two tumor cell lines (HeLa, WM35) and on a normal cell line (HFL1) using the MTT method, with cisplatin used as a positive control. The antibacterial activity of the complexes was investigated against two Gram-positive and two Gram-negative bacteria, and compared with Amoxicillin and Norfloxacin using the disk diffusion method. Both complexes showed in vitro biological activity but the C2 complex was more active. A lack of in vivo toxicity was demonstrated for the C2 complex by performing hepatic, renal, and hematological studies on Swiss mice.

Citing Articles

Metal-Based Drug-DNA Interactions and Analytical Determination Methods.

Hangan A, Oprean L, Dican L, Procopciuc L, Sevastre B, Lucaciu R Molecules. 2024; 29(18).

PMID: 39339356 PMC: 11434005. DOI: 10.3390/molecules29184361.


Synthesis, characterization, biological potency, and molecular docking of Co, Ni and Cu complexes of a benzoyl isothiocyanate based ligand.

Al-Farraj E, Younis A, El-Reash G Sci Rep. 2024; 14(1):10032.

PMID: 38693156 PMC: 11063136. DOI: 10.1038/s41598-024-58108-5.


New Copper Complexes with Antibacterial and Cytotoxic Activity.

Hangan A, Lucaciu R, Turza A, Dican L, Sevastre B, Pall E Int J Mol Sci. 2023; 24(18).

PMID: 37762121 PMC: 10530662. DOI: 10.3390/ijms241813819.


Metallo-Drugs in Cancer Therapy: Past, Present and Future.

Lucaciu R, Hangan A, Sevastre B, Oprean L Molecules. 2022; 27(19).

PMID: 36235023 PMC: 9572156. DOI: 10.3390/molecules27196485.

References
1.
Denoyer D, Clatworthy S, Cater M . Copper Complexes in Cancer Therapy. Met Ions Life Sci. 2018; 18. DOI: 10.1515/9783110470734-022. View

2.
Sathisha M, Shetti U, Revankar V, Pai K . Synthesis and antitumor studies on novel Co(II), Ni(II) and Cu(II) metal complexes of bis(3-acetylcoumarin)thiocarbohydrazone. Eur J Med Chem. 2007; 43(11):2338-46. DOI: 10.1016/j.ejmech.2007.10.003. View

3.
van Rijt S, Sadler P . Current applications and future potential for bioinorganic chemistry in the development of anticancer drugs. Drug Discov Today. 2009; 14(23-24):1089-97. PMC: 2933823. DOI: 10.1016/j.drudis.2009.09.003. View

4.
Sundberg J, Witt H, Cameron L, Hakansson M, Bendix J, McKenzie C . A versatile dinucleating ligand containing sulfonamide groups. Inorg Chem. 2014; 53(6):2873-82. DOI: 10.1021/ic402599e. View

5.
Molinaro C, Wambang N, Bousquet T, Vercoutter-Edouart A, Pelinski L, Cailliau K . A Novel Copper(II) Indenoisoquinoline Complex Inhibits Topoisomerase I, Induces G2 Phase Arrest, and Autophagy in Three Adenocarcinomas. Front Oncol. 2022; 12:837373. PMC: 8908320. DOI: 10.3389/fonc.2022.837373. View